Founded in 1992, Fosun International is one of the representative companies emerging in the reform of China market-oriented economy. On 2007 July 16, Fosun International (00656.HK) was listed on the main board of the Hong Kong Stock Exchange. As a technology-driven consumer group, Fosun operates three business lines, in Health, Happiness and Wealth, creating high-quality products and services for families around the world. Fosun has focused heavily on enhancing operations across our global core business. In particular, we have focused on creating world class products and brands, improving global sales and marketing and driving operational efficiency. We continue to promote our 1+N strategy and formed a couple of market leaders across multiple product lines under Fosun, such as Hanlikan (China's first self-developed biosimilar in China), Fosun United Health Insurance (professional health insurance provider), Chancheng Hospital ( ranked 1st in Chinese non-public hospital over recent 3 years), Club Med (the world's largest resort operator), and Atlantis Sanya (the benchmark for Sanya tourism), etc. Moreover, we plan to create more market leading brands. In 2018, the total revenue of Fosun International reached 109.4bn RMB (around 16.5bn USD). Until 2019 Jun 30th, total asset of Fosun International is 681.51bn RMB(around 99.1bn USD).
|Registered Office||Room 808, ICBC Tower 3 Garden Road Central Hong Kong|
|Principal Place of Business in the PRC||
Tower S1, Bund Finance Center, 600 Zhongshan No. 2 Road(E), Shanghai, China
|Executive Directors||Guangchang Guo, Qunbin Wang, Qiyu Chen, Xiaoliang Xu, Xuetang Qin, Can Wang, Ping Gong|
|Independent Non-Executive Directors||Zhang Shengman, Zhang Huaqiao, David T. Zhang, Yang Chao, Lee Kai-Fu|
|Company Secretary||Sze Mei Ming|
|Auditor||Ernst & Young|